Ministry of Health
Circular of
Indications for use of the VidPrevtyn Beta (Sanofi) vaccine as part of the anti-Sars-CoV-2/Covid-19 vaccination campaign
The Technical Scientific Commission of AIFA, in the session of , accepting the opinion expressed by the European Medicines Agency (EMA), approved the indication of use of the VidPrevtyn Beta vaccine (Sanofi), as a booster dose for active immunization in the prevention of COVID-19 in adults who have previously received an mRNA or adenoviral vector-based anti-COVID-19 vaccine.Therefore, taking into account the opinion expressed by the CTS, VidPrevtyn Beta is included in the SARS-CoV-2/COVID-19 vaccination program, as a heterologous booster dose, if the administration of a bivalent mRNA vaccine is not considered appropriate, at least 120 days after the last dose of vaccine received. The vaccine can be used from 18 years of age. The vaccine is authorised to be given only once (subsequent boosters with the same vaccine are not yet authorised). The vaccine is not authorised for the primary cycle and can only be used as a booster dose.
— Reproduction reserved and for personal use
— Download the full document in PDF format from the link at the bottom of the page
Access to the site is limited and reserved for healthcare professionals
You have reached the maximum number of visits
Source — https://www.univadis.it/viewarticle/indicazioni-di-utilizzo-del-vaccino-vidprevtyn-beta-sanofi-nellambito-della-campagna-di-vaccinazione-anti-sars-cov-2covid-19